Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.
Hiroshi Onishi,Hiroki Shirato,Yasushi Nagata,Masahiro Hiraoka,Masaharu Fujino,Kotaro Gomi,Yuzuru Niibe,Katsuyuki Karasawa,Kazushige Hayakawa,Yoshihiro Takai,Tomoki Kimura,A. Takeda,Atsushi Ouchi,Masato Hareyama,Masaki Kokubo,Ryusuke Hara,Jun Itami,Kazunari Yamada,Tsutomu Araki +18 more
Reads0
Chats0
TLDR
HypoFXSRT with a BED of less than 180 Gy was almost safe for stage I NSCLC, and the local control and overall survival rates in 5 years with a AED of 100 Gy or more were superior to the reported results for conventional radiotherapy.About:
This article is published in Journal of Thoracic Oncology.The article was published on 2007-07-01 and is currently open access. It has received 880 citations till now. The article focuses on the topics: Survival rate.read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Stanley H Benedict,Kamil M. Yenice,David S Followill,James M. Galvin,William H. Hinson,Brian D. Kavanagh,Paul J. Keall,Michael Lovelock,Sanford L. Meeks,Lech Papiez,Thomas G. Purdie,R Sadagopan,Michael C. Schell,Bill J. Salter,David Schlesinger,Almon S. Shiu,Timothy D. Solberg,Danny Y. Song,Volker W. Stieber,Robert Timmerman,Wolfgang A. Tomé,Dirk Verellen,Lu Wang,Fang-Fang Yin +23 more
TL;DR: The task group report includes a review of the literature to identify reported clinical findings and expected outcomes for this treatment modality.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
TL;DR: Surgical resection remains the primary and preferred approach to the treatment of stage I and II NSCLC, and mediastinal lymph node sampling at the time of curative intent surgical resection can be performed without increased morbidity.
Journal ArticleDOI
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
Pia Baumann,Jan Nyman,Morten Høyer,Berit Wennberg,Giovanna Gagliardi,Ingmar Lax,Ninni Drugge,Lars Ekberg,Signe Friesland,Karl-Axel Johansson,Jo-Åsmund Lund,Elisabeth Morhed,Kristina Nilsson,Nina Levin,Merete Paludan,Christer Sederholm,Anders Traberg,Lena Wittgren,Rolf Lewensohn +18 more
TL;DR: With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
New guidelines to evaluate the response to treatment in solid tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: In this article, the authors proposed a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment.
Journal ArticleDOI
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study.
Hiroshi Onishi,Tsutomu Araki,Hiroki Shirato,Yasushi Nagata,Masahiro Hiraoka,Kotaro Gomi,Takashi Yamashita,Yuzuru Niibe,Katsuyuki Karasawa,Kazushige Hayakawa,Yoshihiro Takai,Tomoki Kimura,Yutaka Hirokawa,Atsuya Takeda,Atsushi Ouchi,Masato Hareyama,Masaki Kokubo,Ryusuke Hara,Jun Itami,Kazunari Yamada +19 more
TL;DR: Stereotactic irradiation has been actively performed using various methods to achieve better local control of Stage I nonsmall cell lung carcinoma in Japan and results from a Japanese multiinstitutional study are retrospectively evaluated.
Journal ArticleDOI
Extracranial Stereotactic Radioablation*: Results of a Phase I Study in Medically Inoperable Stage I Non-small Cell Lung Cancer
Robert Timmerman,Lech Papiez,Ronald McGarry,Laura Likes,Colleen DesRosiers,Stephanie Frost,Mark Richard James Williams +6 more
TL;DR: Very high radiation dose treatments were tolerated in this population of medically inoperable patients with stage I NSCLC using ESR techniques.
Journal ArticleDOI
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame
Yasushi Nagata,Kenji Takayama,Yukinori Matsuo,Yoshiki Norihisa,Takashi Mizowaki,Takashi Sakamoto,M. Sakamoto,Michihide Mitsumori,Keiko Shibuya,Norio Araki,Shinsuke Yano,Masahiro Hiraoka +11 more
TL;DR: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereOTactic body frame is useful for the treatment of Stage I lung tumors.